Abstract
Objectives To describe histopathologic findings in the placentas of women with COVID-19 during pregnancy.
Methods Pregnant women with COVID-19 delivering between March 18, 2020 and May 5, 2020 were identified. Placentas were examined and compared to historical controls and women with placental evaluation for a history of melanoma.
Results 16 placentas from patients with SARS-CoV-2 were examined (15 with live birth in the 3rd trimester 1 delivered in the 2nd trimester after intrauterine fetal demise). Compared to controls, third trimester placentas were significantly more likely to show at least one feature of maternal vascular malperfusion (MVM), including abnormal or injured maternal vessels, as well as delayed villous maturation, chorangiosis, and intervillous thrombi. Rates of acute and chronic inflammation were not increased.
The placenta from the patient with intrauterine fetal demise showed villous edema and a retroplacental hematoma.
Conclusions Relative to controls, COVID-19 placentas show increased prevalence of features of maternal vascular malperfusion (MVM), a pattern of placental injury reflecting abnormalities in oxygenation within the intervillous space associated with adverse perinatal outcomes. Only 1 COVID-19 patient was hypertensive despite the association of MVM with hypertensive disorders and preeclampsia. These changes may reflect a systemic inflammatory or hypercoagulable state influencing placental physiology.
Key Points
The placentas of women infected with SARS-CoV2 have higher rates maternal vascular malperfusion features compared to controls.
Maternal vascular malperfusion has been associated with adverse perinatal outcomes, such as preeclampsia, fetal growth restriction, preterm birth, and stillbirth.
As the placentas of women with SARS-CoV2 show reproducible histopathologic abnormalities, these findings suggest increased antenatal surveillance for women with COVID-19 may be warranted.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors received no specific funding for this work. This study was completed using REDCap at Northwestern University, which is supported by UL1TR001422.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclosure: The authors received no specific funding for this work. Patients were tracked using REDCap supported by NIH UL1TR001422.
Conflict of Interest: The authors report no conflict of interest.
Data Availability
Original data are available following execution of a Data Use Agreement with Northwestern University.
